Evidence map›Paper›PMID 35078853›Full record

ArticleBMJ open2022

Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma-a phase 3 randomised trial.

Peey Sei Kok, Patrick M Forde, Brett Hughes, Zhuoxin Sun, Chris Brown, Suresh Ramalingam, Alistair Cook, Willem Joost Lesterhuis, Sonia Yip, Ken O'Byrne and 10 more

Registry-linked trialOpen access · goldAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04334759 (DREAM3R), which is not on this map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04334759 phase3completednot on this map

DREAM3R: DuRvalumab (MEDI4736) With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma - A Phase 3 Randomised Trial

TypeinterventionalSponsorPrECOG, LLC.Ran2021 to 2025Enrolled214ConditionsMesothelioma, Pleural Mesothelioma, Malignant Pleural MesotheliomaArmsDurvalumab, Standard Chemotherapy, Ipilimumab and Nivolumab
3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 28 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Article
  5. [Recent Advances in Medical Treatment of Malignant Pleural Mesothelioma].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025
    Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 9 institutions in 3 countries.

Peey Sei KokNHMRC Clinical Trials Centre, University of Sydney, Camperdown, New South Wales, Australia peey-sei.kok@sydney.edu.au.ORCID 0000-0002-4910-4615
Patrick M FordeBloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA.
Brett HughesMedical Oncology, Royal Brisbane and Women's Hospital, Herston, Queensland, Australia.
Zhuoxin SunECOG-ACRIN Biostatistics Center, Frontier Science Foundation, Boston, Massachusetts, USA.
Chris BrownNHMRC Clinical Trials Centre, University of Sydney, Camperdown, New South Wales, Australia.
Suresh RamalingamWinship Cancer Institute, Emory University, Atlanta, Georgia, USA.
Alistair CookNational Centre for Asbestos Related Diseases (NCARD), Institute for Respiratory Health, Perth, Western Australia, Australia.
Willem Joost LesterhuisTelethon Kids Institute, Nedlands, Western Australia, Australia.
Sonia YipNHMRC Clinical Trials Centre, University of Sydney, Camperdown, New South Wales, Australia.
Ken O'ByrneMedical Oncology, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia.
Nick PavlakisGenesis Care, Sydney, New South Wales, Australia.
Julie BrahmerBloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA.
Valsamo AnagnostouBloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA.
Kate FordNHMRC Clinical Trials Centre, University of Sydney, Camperdown, New South Wales, Australia.
Karen FitzpatrickPrECOG, Philadelphia, Pennsylvania, USA.
Alison BrickerPrECOG, Philadelphia, Pennsylvania, USA.
Michelle M CumminsNHMRC Clinical Trials Centre, University of Sydney, Camperdown, New South Wales, Australia.
Martin StocklerNHMRC Clinical Trials Centre, University of Sydney, Camperdown, New South Wales, Australia.
Anna K NowakNational Centre for Asbestos Related Diseases (NCARD), Institute for Respiratory Health, Perth, Western Australia, Australia.
Thoracic Oncology Group of Australasia (TOGA) and PrECOG, USA
The University of Sydney · AUBloomberg (United States) · USThe University of Western Australia · AUCamden and Campbelltown Hospitals · AUEmory University · USFrontier Science Foundation · CHQueensland University of Technology · AUThe Kids Research Institute Australia · AUThe University of Queensland · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThere is a strong theoretical rationale for combining checkpoint blockade with cytotoxic chemotherapy in pleural mesothelioma and other cancers. Two recent single-arm, phase 2 trials [DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma (DREAM) and Phase II multicenter study of anti-PD-L1, durvalumab, in combination with cisplatin and pemetrexed for the first-line treatment of unresectable malignant pleural mesothelioma (PrE0505)] combining the programmed death ligand-1 (PD-L1) inhibitor durvalumab with standard first-line chemotherapy exceeded prespecified safety and activity criteria to proceed to a phase 3 confirmatory trial to assess this combination. We present the protocol of the DREAM3R trial. METHODS AND ANALYSIS: This multicentre open-label randomised trial will recruit 480 treatment-naïve adults with advanced pleural mesothelioma, randomised (2:1) to either 3-weekly durvalumab 1500 mg plus 3-weekly doublet chemotherapy (cisplatin 75 mg/m ETHICS AND DISSEMINATION: The protocol was approved by human research ethics review committees for all participating sites. Results will be disseminated in peer-reviewed journals and at scientific conferences. DRUG SUPPLY: AstraZeneca. PROTOCOL VERSION: CTC 0231 / TOGA 18/001 / PrE0506 3.0, 29 July 2021. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov Identifier: NCT04334759 ACTRN 12620001199909.

Indexed as

Lung NeoplasmsMesotheliomaMesothelioma, MalignantAdolescentAdultAgedAntibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsClinical Trials, Phase III as TopicHumansMiddle AgedMulticenter Studies as TopicQuality of LifeRandomized Controlled Trials as TopicYoung AdultAntibodies, Monoclonaldurvalumabchemotherapyimmunologyoncologyrespiratory tract tumours

Identifiers

PMID35078853
PMCPMC8796233
OpenAlexW4206964867

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.